Boehringer Ingelheim has entered into a multi-year strategic partnership with TARGET PharmaSolutions, a real-world clinical data company, for an observational study TARGET-NASH.
This study is evaluating patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) and has enrolled 2,423 patients at 55 sites, with the expectation to enroll as many as 15,000 patients over the coming years.
The TARGET model organizes a community of stakeholders, including pharmaceutical manufacturers, key opinion leaders, regulatory agencies, investigators, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes.
Meg Powell, chief executive officer of TARGET PharmaSolutions, said, "We are very excited to have Boehringer Ingelheim join TARGET-NASH as an industry partner. We have exceeded our enrollment targets to date, and we are providing valuable real-world data and insight on NASH patients that will have a significant impact on the scientific understanding of the natural history and treatment modalities for NASH. This data, combined with the TARGET-NASH biorepository and patient reported outcomes, will enable our collaborators to continue to increase their understanding of this growing disease."
Breaking News
Boehringer, TARGET Pharma in Strategic NASH Pact
Observational study to incorporate TARGET model of community of stakeholders
10.19.17
Related Breaking News
-
Clinical Trials | Collaborations & Alliances | Industry News | R&D
Takeda, Ovid Detail Clinical Development Program
The companies plan to initiate three clinical trials to investigate the potential of TAK-935/OV93507.18.18
-
Breaking News | Industry News | Information Technology | Packaging & Tracking | Serialization
SEA Vision Expands Global Presence With €1.5mn Investment
Opening new offices in the U.S., Germany and Russia07.18.18
-
Bio News | Clinical Trials | Industry News | R&D
Roche Phase III Study Meets Primary Objective
Assessing the safety and efficacy of baloxavir marboxil in people at high risk of complications from the flu07.17.18
-
Clinical Trials | Drug Development | Industry News | Information Technology
CluePoints, ONO in Four-Year RBM Pact
ONO will utilize CluePoints’ centralized statistical monitoring platform07.13.18
-
Breaking News | Industry News | Information Technology | Packaging & Tracking | Serialization
TraceLink Unveils Product Information Manager
Standards-based network application for its digital information sharing platform07.11.18
-
Clinical Trials | Drug Development | Industry News | Information Technology | R&D
Sanofi Launches Global R&D Ops in China
New global R&D operations hub focused on digitalization and big data analysis07.02.18
-
Clinical Trials | Collaborations & Alliances | Industry News
Kymab, Roche Partner to Evaluate KY1044
Roche to provide PD-L1 blocking antibody atezolizumab in combination in Kymab’s upcoming Phase I-II clinical studies06.28.18
-
Clinical Trials | Drug Development | Information Technology
Report Reveals Drug Development Innovations Positively Impact Trial Timelines
Adaptive, patient-centric, precision medicine, and real-world data trials increase likelihood of market launch by 10-21%06.25.18
-
Bioanalytical Services | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | Information Technology
Comprehend Systems Joins Veeva Partner Program
To integrate solutions with Veeva Vault EDC & CTMS to provide pharma companies real-time performance & risk monitoring06.21.18
-
Clinical Trials | CRO News | Information Technology
ICON Enhances Endpoint Adjudication Services
Will leverage AG Mednet's comprehensive electronic endpoint adjudication system06.11.18
-
Drug Discovery | Industry News | Information Technology
WuXi AppTec Invests in Insilico Medicine
Aims to accelerate drug discovery using next-gen artificial intelligence06.11.18
-
Bio News | Breaking News | Clinical Trials | Collaborations & Alliances | Drug Development | Drug Discovery
GE, XPH Enter FlexFactory Agreement
To scale up, digitize & accelerate manufacturing processes for their cell therapy clinical trials & future commercialization06.07.18
-
Bioanalytical Services | Collaborations & Alliances | Industry News | Information Technology
"Research With NJ" Database Launches at BIO
The portal is structured to encourage collaboration between entrepreneurs, businesses, & NJ's academic research institutions06.05.18
-
Clinical Trials | CRO News | Laboratory Testing
ACM Global Labs Adds New Testing Services for Oncology Trials
Introduces therapeutic service offering to support the specific testing needs of oncology clinical trials06.01.18
-
Breaking News | Clinical Trials | Collaborations & Alliances | Industry News
PPD and NeoGenomics Form Global Strategic Alliance
Expanding global oncology testing for clinical trials06.01.18
